Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Truist Financial Corp

Truist Financial Corp reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,406 shares of the specialty pharmaceutical company’s stock after selling 2,177 shares during the quarter. Truist Financial Corp owned about 0.06% of Jazz Pharmaceuticals worth $4,847,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Los Angeles Capital Management LLC increased its holdings in Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after buying an additional 273,764 shares during the period. Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 28.1% in the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock worth $125,916,000 after purchasing an additional 224,865 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its holdings in shares of Jazz Pharmaceuticals by 242.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after purchasing an additional 191,648 shares in the last quarter. Aristotle Capital Management LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter valued at $22,748,000. Finally, Federated Hermes Inc. boosted its stake in shares of Jazz Pharmaceuticals by 1,105.6% during the 3rd quarter. Federated Hermes Inc. now owns 123,635 shares of the specialty pharmaceutical company’s stock worth $16,003,000 after acquiring an additional 113,380 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research reports. Truist Financial reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday. Piper Sandler raised their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. UBS Group lowered their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Finally, Stifel Nicolaus raised their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $192.75.

Insider Buying and Selling

In other news, CFO Philip L. Johnson bought 12,000 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $110.01 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.85 and a debt-to-equity ratio of 1.38. Jazz Pharmaceuticals plc has a 12-month low of $103.01 and a 12-month high of $146.70. The company has a market cap of $6.94 billion, a price-to-earnings ratio of 22.68, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The stock has a 50 day simple moving average of $116.44 and a 200-day simple moving average of $120.94.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.